Murepavadin: a new antibiotic class in the pipeline

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16

(2017) David M Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Structural and Functional Characterization of the LPS Transporter LptDE from Gram-Negative Pathogens

(2016) Istvan Botos et al.   STRUCTURE

Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

(2015) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Peptidomimetic Antibiotic Targets Outer Membrane Proteins and Disrupts Selectively the Outer Membrane inEscherichia coli

(2015) Matthias Urfer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms

(2015) Ignacio Martin-Loeches et al.   JOURNAL OF INFECTION

Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa*

(2014) Marin H. Kollef et al.   CRITICAL CARE MEDICINE

Risks for multidrug-resistant pathogens in the ICU

(2014) Ignacio Martín-Loeches et al.   Current Opinion in Critical Care

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)

(2014) Helio S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides

(2013) Lei Diao et al.   CLINICAL PHARMACOKINETICS

Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients

(2013) Mario Tumbarello et al.   INTENSIVE CARE MEDICINE

Prospects for new antibiotics: a molecule-centered perspective

(2013) Christopher T Walsh et al.   JOURNAL OF ANTIBIOTICS

Inhibition of Lipopolysaccharide Transport to the Outer Membrane in Pseudomonas aeruginosa by Peptidomimetic Antibiotics

(2012) Martina Werneburg et al.   CHEMBIOCHEM

The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: An important determinant of outcome

(2012) John G. Muscedere et al.   JOURNAL OF CRITICAL CARE

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

(2010) Brad Spellberg et al.   CLINICAL INFECTIOUS DISEASES

Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

(2010) Ronald N. Jones   CLINICAL INFECTIOUS DISEASES

Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa

(2010) N. Srinivas et al.   SCIENCE

To protect peptide pharmaceuticals against peptidases

(2010) R. Rink et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE

(2008) Louis B. Rice   JOURNAL OF INFECTIOUS DISEASES